Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Clasificación en acciones #16882
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Precio por acción
$2.52
Capitalización bursátil
$274.65M
Cambio (1 día)
0.46%
Cambio (1 año)
-56.11%
País
CN
Comercio VISEN Pharmaceuticals (2561)

Categoría

Ganancias de VISEN Pharmaceuticals (2561)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di VISEN Pharmaceuticals, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de VISEN Pharmaceuticals desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras